While protection from NAFLD induced by hepatocyte-specific deletion of GPX1 and HMOX1 in mice is a proof of concept that excessive antioxidant function can promote NAFLD, no therapeutic strategies and trials aimed to decrease antioxidant activity in human livers. The gene discussed is HMOX1; the disease is metabolic dysfunction-associated steatotic liver disease.